The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220306994.
Chimeric Cells Comprising Dendritic Cells and Endothelial Cells Resembling Tumor Endothelium
Abstract
Disclosed are means, methods and compositions of matter useful for induction of immunological responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction. In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.